Screener
Jade Biosciences JBIO Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Jade Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:27 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212088
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Change in fair value of Convertible Notes payable | — | 15,400 |
| Stock-based compensation | 7,405 | 2,423 |
| Non-cash lease expense | 26 | 8 |
| Accretion/amortization on investments | (493) | — |
| Depreciation expense | 9 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 5,444 | (507) |
| Other assets | — | (60) |
Item 1. Financial Statements.
FAQ
- What is Jade Biosciences's accretion (amortization) of discounts and premiums, investments?
- Jade Biosciences (JBIO) reported accretion (amortization) of discounts and premiums, investments of $493K in Q1 2026.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This metric accounts for the non-cash adjustment to the carrying value of investment securities, reflecting the gradual recognition of interest income or expense over time. It represents the difference between the purchase price and the face value of debt securities held in the company's treasury. It is used to reconcile net income with actual cash flows generated from investment holdings.
Ask your AI about Jade Biosciences's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude